{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:17:59Z","timestamp":1789586279352,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study\u00a0investigated the agreement between various dried blood spot (DBS) and venous blood sample measurements of phenylalanine and tyrosine concentrations in Phenylketonuria (PKU) and Tyrosinemia type 1 (TT1) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Phenylalanine and tyrosine concentrations were studied in 45 PKU\/TT1 patients in plasma from venous blood in lithium heparin (LH) and EDTA tubes; venous blood from LH and EDTA tubes on a DBS card; venous blood directly on a DBS card; and capillary blood on a DBS card. Plasma was analyzed with an amino acid analyzer and DBS were analyzed with liquid chromatography-mass spectrometry. Agreement between different methods was assessed using Passing and Bablok fit and Bland Altman analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In general, phenylalanine concentrations in LH plasma were comparable to capillary DBS, whereas tyrosine concentrations were slightly higher in LH plasma (constant bias of 6.4\u2009\u03bcmol\/L). However, in the low phenylalanine range, most samples had higher phenylalanine concentrations in DBS compared to LH plasma. Remarkably, phenylalanine and tyrosine in EDTA plasma were higher compared to all other samples (slopes ranging from 7 to 12%). No differences were observed when comparing capillary DBS to other DBS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall agreement between plasma and DBS is good. However, bias is specimen- (LH vs EDTA), and possibly concentration- (low phenylalanine) dependent. Because of the overall good agreement, we recommend the use of a DBS-plasma correction factor for DBS measurement. Each laboratory should determine their own factor dependent on filter card type, extraction and calibration protocols taking the LH plasma values as gold standard.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-020-1343-7","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T07:18:31Z","timestamp":1585898311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Dried blood spot versus venous blood sampling for phenylalanine and tyrosine"],"prefix":"10.1186","volume":"15","author":[{"given":"Kimber","family":"van Vliet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiggert G.","family":"van Ginkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim","family":"de Blaauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Koehorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermi A.","family":"Kingma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francjan J.","family":"van Spronsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3477-0770","authenticated-orcid":false,"given":"M. Rebecca","family":"Heiner-Fokkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"issue":"9","key":"1343_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(16)30320-5","volume":"5","author":"FJ van Spronsen","year":"2017","unstructured":"van Spronsen FJ, van Wegberg AM, Ahring K, B\u00e9langer-Quintana A, Blau N, Bosch AM, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743\u201356.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1343_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","volume":"12","author":"AM van Wegberg","year":"2017","unstructured":"van Wegberg AM, MacDonald A, Ahring K, B\u00e9langer-Quintana A, Blau N, Bosch AM, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1343_CR3","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1111\/1467-8624.00370","volume":"72","author":"M Luciana","year":"2001","unstructured":"Luciana M, Sullivan J, Nelson CA. Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria. Child Dev. 2001;72(6):1637\u201352.","journal-title":"Child Dev"},{"key":"1343_CR4","doi-asserted-by":"crossref","unstructured":"Chinsky JM, Singh R, Ficicioglu C, van Karnebeek CD, Grompe M, Mitchell G, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017;19(12)..","DOI":"10.1038\/gim.2017.101"},{"key":"1343_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/8904_2014_358","volume":"18","author":"D van Vliet","year":"2015","unstructured":"van Vliet D, van Dam E, van Rijn M, Derks TG, Venema-Liefaard G, Hitzert MM, et al. Infants with Tyrosinemia type 1: should phenylalanine be supplemented? JIMD Rep. 2015;18:117\u201324.","journal-title":"JIMD Rep"},{"key":"1343_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymgmr.2017.01.016","volume":"11","author":"MI Garc\u00eda","year":"2017","unstructured":"Garc\u00eda MI, de la Parra A, Arias C, Arredondo M, Cabello JF. Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet. Mol Genet Metab Rep. 2017;11:12\u20136.","journal-title":"Mol Genet Metab Rep."},{"issue":"9","key":"1343_CR7","doi-asserted-by":"publisher","first-page":"e0185342","DOI":"10.1371\/journal.pone.0185342","volume":"12","author":"WG van Ginkel","year":"2017","unstructured":"van Ginkel WG, van Vliet D, Burgerhof JG, de Blaauw P, Rubio Gozalbo ME, Heiner-Fokkema MR, et al. Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1. PLoS One. 2017;12(9):e0185342.","journal-title":"PLoS One"},{"key":"1343_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/8904_2017_69","volume":"40","author":"H Walker","year":"2018","unstructured":"Walker H, Pitkanen M, Rahman Y, Barrington SF. Three cases of hereditary Tyrosinaemia type 1: neuropsychiatric outcomes and brain imaging following treatment with NTBC. JIMD Rep. 2018;40:97\u2013103.","journal-title":"JIMD Rep."},{"key":"1343_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ymgmr.2016.01.001","volume":"6","author":"BM Stroup","year":"2016","unstructured":"Stroup BM, Held PK, Williams P, Clayton MK, Murali SG, Rice GM, et al. Clinical relevance of the discrepancy in phenylalanine concentrations analyzed using tandem mass spectrometry compared with ion-exchange chromatography in phenylketonuria. Mol Genet Metab Rep. 2016;6:21\u20136.","journal-title":"Mol Genet Metab Rep"},{"issue":"10","key":"1343_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.clinbiochem.2004.06.004","volume":"37","author":"P Allard","year":"2004","unstructured":"Allard P, Cowell LD, Zytkovicz TH, Korson MS, Ampola MG. Determination of phenylalanine and tyrosine in dried blood specimens by ion-exchange chromatography using the Hitachi L-8800 analyzer. Clin Biochem. 2004;37(10):857\u201362.","journal-title":"Clin Biochem"},{"issue":"11","key":"1343_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/GIM.0b013e318159a355","volume":"9","author":"CO Gregory","year":"2007","unstructured":"Gregory CO, Yu C, Singh RH. Blood phenylalanine monitoring for dietary compliance among patients with phenylketonuria: comparison of methods. Genet Med. 2007;9(11):761\u20135.","journal-title":"Genet Med"},{"issue":"1\u20132","key":"1343_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.clinbiochem.2014.09.014","volume":"48","author":"U Groselj","year":"2015","unstructured":"Groselj U, Murko S, Tansek MZ, Kovac J, Bakija AT, Lampret BR, et al. Comparison of tandem mass spectrometry and amino acid analyzer for phenylalanine and tyrosine monitoring--implications for clinical management of patients with hyperphenylalaninemia. Clin Biochem. 2015;48(1\u20132):14\u20138.","journal-title":"Clin Biochem"},{"issue":"2","key":"1343_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-277X.2011.01215.x","volume":"25","author":"A Daly","year":"2012","unstructured":"Daly A, Gokmen-Ozel H, MacDonald A, Preece MA, Davies P, Chakrapani A, et al. Diurnal variation of phenylalanine concentrations in tyrosinaemia type 1: should we be concerned? J Hum Nutr Diet. 2012;25(2):111\u20136.","journal-title":"J Hum Nutr Diet"},{"key":"1343_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/8904_2016_37","volume":"36","author":"E van Dam","year":"2017","unstructured":"van Dam E, Daly A, Venema-Liefaard G, van Rijn M, Derks TG, McKiernan PJ, et al. What is the best blood sampling time for metabolic control of phenylalanine and tyrosine concentrations in Tyrosinemia type 1 patients? JIMD Rep. 2017;36:49\u201357.","journal-title":"JIMD Rep."},{"issue":"6","key":"1343_CR15","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/ajcn\/64.6.916","volume":"64","author":"FJ van Spronsen","year":"1996","unstructured":"van Spronsen FJ, van Dijk T, Smit GP, van Rijn M, Reijngoud DJ, Berger R, et al. Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria. Am J Clin Nutr. 1996;64(6):916\u201321.","journal-title":"Am J Clin Nutr"},{"key":"1343_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ymgme.2011.08.010","volume":"104 Suppl","author":"M van Rijn","year":"2011","unstructured":"van Rijn M, Hoeksma M, Sauer PJ, Modderman P, Reijngoud D, van Spronsen FJ. Diurnal variations in blood phenylalanine of PKU infants under different feeding regimes. Mol Genet Metab. 2011;104 Suppl:68.","journal-title":"Mol Genet Metab"},{"key":"1343_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cca.2016.01.026","volume":"455","author":"S Takehana","year":"2016","unstructured":"Takehana S, Yoshida H, Ozawa S, Yamazaki J, Shimbo K, Nakayama A, et al. The effects of pre-analysis sample handling on human plasma amino acid concentrations. Clin Chim Acta. 2016;455:68\u201374.","journal-title":"Clin Chim Acta"},{"issue":"12","key":"1343_CR18","doi-asserted-by":"publisher","first-page":"e0143833","DOI":"10.1371\/journal.pone.0143833","volume":"10","author":"D van Vliet","year":"2015","unstructured":"van Vliet D, Bruinenberg VM, Mazzola PN, van Faassen MH, de Blaauw P, Kema IP, et al. Large neutral amino acid supplementation exerts its effect through three synergistic mechanisms: proof of principle in phenylketonuria mice. PLoS One. 2015;10(12):e0143833.","journal-title":"PLoS One"},{"key":"1343_CR19","unstructured":"Clinical and Laboratory Standards Institute (CLSI). EP09-A3: Measurement Procedure Comparison and Bias Estimation Using Patient Samples, 3rd Edition. Wayne: Clinical and Laboratory Standards Institute; 2013."},{"issue":"1","key":"1343_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.11613\/BM.2011.010","volume":"21","author":"L Bili\u0107-Zulle","year":"2011","unstructured":"Bili\u0107-Zulle L. Comparison of methods: passing and Bablok regression. Biochem Med (Zagreb). 2011;21(1):49\u201352.","journal-title":"Biochem Med (Zagreb)"},{"issue":"2","key":"1343_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S0022-3476(66)80327-X","volume":"69","author":"BM Rouse","year":"1966","unstructured":"Rouse BM. Phenylalanine deficiency syndrome. J Pediatr. 1966;69(2):246\u20139.","journal-title":"J Pediatr"},{"issue":"3","key":"1343_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ymgme.2018.06.010","volume":"125","author":"R Zori","year":"2018","unstructured":"Zori R, Thomas JA, Shur N, Rizzo WB, Decker C, Rosen O, et al. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria. Mol Genet Metab. 2018;125(3):217\u201327.","journal-title":"Mol Genet Metab"},{"issue":"9937","key":"1343_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(13)61841-3","volume":"384","author":"N Longo","year":"2014","unstructured":"Longo N, Harding CO, Burton BK, Grange DK, Vockley J, Wasserstein M, et al. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014;384(9937):37\u201344.","journal-title":"Lancet."},{"issue":"3","key":"1343_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/mas.21441","volume":"35","author":"M Wagner","year":"2016","unstructured":"Wagner M, Tonoli D, Varesio E, Hopfgartner G. The use of mass spectrometry to analyze dried blood spots. Mass Spectrom Rev. 2016;35(3):361\u2013438.","journal-title":"Mass Spectrom Rev"},{"issue":"1","key":"1343_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0969141315593571","volume":"23","author":"AJ Lawson","year":"2016","unstructured":"Lawson AJ, Bernstone L, Hall SK. Newborn screening blood spot analysis in the UK: influence of spot size, punch location and haematocrit. J Med Screen. 2016;23(1):7\u201316.","journal-title":"J Med Screen"},{"issue":"7","key":"1343_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1515\/CCLM.2002.119","volume":"40","author":"U Ceglarek","year":"2002","unstructured":"Ceglarek U, M\u00fcller P, Stach B, B\u00fchrdel P, Thiery J, Kiess W. Validation of the phenylalanine\/tyrosine ratio determined by tandem mass spectrometry: sensitive newborn screening for phenylketonuria. Clin Chem Lab Med. 2002;40(7):693\u20137.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"1343_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.clinbiochem.2010.06.014","volume":"44","author":"BG Keevil","year":"2011","unstructured":"Keevil BG. The analysis of dried blood spot samples using liquid chromatography tandem mass spectrometry. Clin Biochem. 2011;44(1):110\u20138.","journal-title":"Clin Biochem"},{"issue":"1","key":"1343_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/clinchem\/46.1.126","volume":"46","author":"BW Adam","year":"2000","unstructured":"Adam BW, Alexander JR, Smith SJ, Chace DH, Loeber JG, Elvers LH, et al. Recoveries of phenylalanine from two sets of dried-blood-spot reference materials: prediction from hematocrit, spot volume, and paper matrix. Clin Chem. 2000;46(1):126\u20138.","journal-title":"Clin Chem"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1343-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-1343-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1343-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T19:32:35Z","timestamp":1617391955000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-1343-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1343"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-1343-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.18081\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.18081\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"assertion":[{"value":"28 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The need for formal ethical review was waived by the local ethics committee of the UMCG. The study design was in accordance with the current revision of the Helsinki Declaration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E van Dam has received advisory board fees from Biomarin and Merck Serono. FJ van Spronsen has received advisory board fees from SOBI, Merck Serono, Biomarin, Nutricia, APR, Arla Food int., and Promethera, research grants from SOBI, Merck Serono, Biomarin, Nutricia, Alexion, Codexis, NPKUA, ESPKU and the Tyrosinemia Foundation, honoraria as consultant for Merck Serono, Biomarin, Nutricia, and APR, and honoraria as speaker for Merck Serono, Biomarin, Nutricia, Vitaflo and MendeliKABS. All other authors have indicated that they have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}